IMPROVED DRUG ABSORPTION |
BETTER PATIENT COMPLIANCE

Improving Health

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technologies. 

Our Progressive Pipeline
Our Technology

Neuroendocrine and Metabolic Disorder Solutions

TLANDO®

—————

An FDA approved oral testosterone replacement therapy option not requiring dose titration.

Designed to help restore normal testosterone levels in males.

LEARN MORE

LPCN 2401

—————

Proprietary androgen receptor agonist (ARA), testosterone ester, for obesity management.

LEARN MORE

LPCN 1154

—————

An oral neuro-steroid being developed for the treatment of postpartum depression

LEARN MORE

LPCN 1144

—————

An oral prodrug of bioidentical testosterone being developed for non-cirrhotic NASH.

Developed as a treatment of non-alcoholic steatohepatitis ("NASH").

LEARN MORE

LPCN 1111 (TLANDO XR)

A potentially once-daily oral prodrug of bioidentical testosterone in development for testosterone replacement therapy.

LEARN MORE

LPCN 1148

—————

An oral prodrug of bioidentical testosterone being developed for the management of symptoms associated with cirrhosis. 

An oral prodrug of a bioidentical testosterone product candidate to treat NASH in Cirrhotic patients.

LEARN MORE

LPCN 1107

—————

Oral candidate of 17-alpha hydroxy-progesterone caproate being developed for the prevention of recurrent pre-term birth.

Prevents preterm birth in women with a prior history of at least one preterm birth.

LEARN MORE

Changing the Face of Oral Absorption Drugs

OUR PIONEERING LIP'RAL TECHNOLOGY ENABLES EFFICIENT ABSORPTION OF WATER INSOLUBLE DRUGS.

Our unique technology, coupled with our product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b)(2) regulatory pathway strategy. We are focused on metabolic and endocrine disorders such as:

  • Liver Disease (NASH)
  • Low Testosterone (Hypogonadism)
  • Recurrent Pre-Term Birth
  • Postpartum Depression
See How It Works

Press Releases

Browse All Press & Events
Mar 26, 2025

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

48 hour at-home dosing Patient dosing expected in Q2/2025 SALT LAKE CITY, March 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary...

Mar 13, 2025

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results...

Browse All Press & Events

Corporate Presentations

Download Our Presentations

Innovative Pharmaceutical Products

ENHANCING HEALTH & IMPROVING PATIENT COMPLIANCE

See How We're Improving Health
Scroll to Top